Dynavax Technologies Corporation (DVAX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Dynavax Technologies Corp... (DVAX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

12.47

-0.01 (-0.08%)

At close: Jan 14, 2025, 3:59 PM

12.48

0.04%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	10.13
Market Cap	1.64B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.15
PE Ratio (ttm)	83.17
Forward PE	n/a
Analyst	Strong Buy

Ask	13.99
Volume	1,104,982
Avg. Volume (20D)	2,219,724
Open	12.70
Previous Close	12.48
Day's Range	12.31 - 12.74
52-Week Range	9.74 - 14.41
Beta	undefined

About DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a coll...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Feb 19, 2004

Employees 408

Stock Exchange NASDAQ

Ticker Symbol DVAX

Website https://www.dynavax.com

Analyst Forecast

According to 2 analyst ratings, the average rating for DVAX stock is "Strong Buy." The 12-month stock price forecast is $23, which is an increase of 84.37% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Dynavax Technologies Corporation is scheduled to release its earnings on Feb 20, 2025, during market hours.
Analysts project revenue of $71.73M, reflecting a 29.02% YoY growth and earnings per share of 0.04.

Why Price Moved

2 months ago · Source

+8.24%

Dynavax Technologies shares are trading higher aft... Unlock content with Pro Subscription

8 months ago · Source

-0.94%

Dynavax shares are trading lower after the company reported worse-than-expected Q1 financial results.

News

1 month ago · zacks.com

Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionabl...

2 months ago · seekingalpha.com

Dynavax Technologies: What The Stock Buyback Means. What It Doesn't

Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B c...

2 months ago · zacks.com

Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why

Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know

The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn...

2 months ago · zacks.com

Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.

2 months ago · businesswire.com

Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors' and officers' po...